LRRK2
LRRK2 inhibitors are compounds that target and inhibit the activity of Leucine-Rich Repeat Kinase 2 (LRRK2), an enzyme involved in several cellular processes, including autophagy, vesicle trafficking, and inflammation. Mutations in the LRRK2 gene are associated with an increased risk of developing Parkinson's disease, making LRRK2 a significant target for neurodegenerative disease research. Inhibitors of LRRK2 are crucial for exploring its role in Parkinson's disease and for developing potential therapeutic strategies. At CymitQuimica, we offer a selection of LRRK2 inhibitors to support your research in neurodegeneration, kinase signaling, and therapeutic development.
Found 45 products for "LRRK2".
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
IKK 16
CAS:IKK 16 (IKK Inhibitor VII) is a selective IκB kinase (IKK) inhibitor for IKK-2, IKK complex and IKK-1 with IC50 of 40 nM, 70 nM and 200 nM, respectively.Formula:C28H29N5OSPurity:98.76% - 99.61%Color and Shape:SolidMolecular weight:483.63Ref: TM-T6176
1mg38.00€2mg50.00€5mg84.00€1mL*10mM (DMSO)93.00€10mg132.00€25mg233.00€50mg385.00€100mg550.00€200mg782.00€CZC-54252
CAS:CZC-54252 is a potent inhibitor of LRRK2.Formula:C22H25ClN6O4SPurity:99.39%Color and Shape:SolidMolecular weight:504.99CZC-25146 hydrochloride
CAS:CZC-25146 is a selective LRRK2 inhibitor with IC50 of 4.76 nM/6.87 nM for wild type LRRK2 and G2019S LRRK2, respectively.Formula:C22H26ClFN6O4SPurity:98.76%Color and Shape:White SolidMolecular weight:525HG-10-102-01
CAS:HG-10-102-01 is an inhibitor of leucine-rich repeat kinase 2 (LRRK2, IC50 of 20.3 nM).Formula:C17H20ClN5O3Purity:99.59%Color and Shape:SolidMolecular weight:377.83Ref: TM-T7196
2mg35.00€5mg55.00€1mL*10mM (DMSO)62.00€10mg89.00€25mg161.00€50mg250.00€100mg360.00€200mg512.00€CZC-25146
CAS:CZC-25146, a stable LRRK2 inhibitor, IC50: 4.76 nM (wild-type), 6.87 nM (G2019S).Formula:C22H25FN6O4SPurity:97.68%Color and Shape:SolidMolecular weight:488.54GNE0877
CAS:GNE0877 (GNE 0877) is a highly effective and specific leucine-rich repeat kinase 2 (LRRK2) inhibitor (Ki: 0.7 nM).Formula:C14H16F3N7Purity:98.01% - 99.97%Color and Shape:White SolidMolecular weight:339.32Ref: TM-T6031
1mg44.00€2mg57.00€1mL*10mM (DMSO)90.00€5mg113.00€10mg177.00€25mg356.00€50mg532.00€100mg760.00€500mg1,558.00€PF-06454589
CAS:PF-06454589 is a potent inhibitor of LRRK2.Formula:C14H16N6OPurity:99.06%Color and Shape:SolidMolecular weight:284.32GNE-9605
CAS:GNE-9605 is a highly effective, specifical, and brain-penetrant LRRK2 inhibitor (IC50: 19 nM).Formula:C17H20ClF4N7OPurity:98.55% - 98.75%Color and Shape:White SolidMolecular weight:449.83GNE-7915
CAS:GNE-7915 is a highly potent, selective and brain-penetrable leucine-rich repeat kinase 2 (LRRK2) inhibitor.Formula:C19H21F4N5O3Purity:98% - ≥95%Color and Shape:SolidMolecular weight:443.4Ref: TM-T1945
5mg44.00€1mL*10mM (DMSO)48.00€10mg58.00€25mg108.00€50mg177.00€100mg299.00€200mg389.00€500mg645.00€PF-06455943
CAS:PF-06455943: LRRK2 inhibitor, IC50=3nM, PET radioligand, used for ADME/neuro PK & Parkinson's research.Formula:C17H14FN5OColor and Shape:SolidMolecular weight:323.32LRRK2-IN-10
CAS:LRRK2-IN-10 (compound 34) is a potent, mutation-selective, brain-penetrant inhibitor targeting G2019S-LRRK2 kinase with IC50 values of 11 nM for G2019S-LRRK2Formula:C20H15N5OPurity:98%Color and Shape:SolidMolecular weight:341.37PF-06371900
CAS:PF-06371900 is a potent and highly selective inhibitor of leucine-rich repeat kinase 2 (LRRK2).Formula:C17H16N6O2SColor and Shape:SolidMolecular weight:368.41LRRK2-IN-7
CAS:LRRK2-IN-7: potent, selective CNS-active LRRK2 inhibitor, IC50 0.9 nM, >1000x selectivity vs kinases/channels/CYPs.Formula:C24H26N6OPurity:99.89%Color and Shape:SolidMolecular weight:414.5LRRK2-IN-6
LRRK2-IN-6 is an oral, selective LRRK2 inhibitor crossing the blood-brain barrier, targeting GS (IC50: 4.6μM) and WT LRRK2 (IC50: 49μM).Formula:C23H24F2N4O2SColor and Shape:SolidMolecular weight:458.52LRRK2-IN-13
CAS:LRRK2-IN-13 (Compound 13), with an IC50 value of 0.57 nM, serves as an inhibitor of LRRK2 and exhibits properties that allow it to penetrate the brain [1].Formula:C19H19ClN8O2Color and Shape:SolidMolecular weight:426.86LRRK2-IN-12
CAS:LRRK2-IN-12 (compound 1) is a potent inhibitor of LRRK2 (G20195) with an IC 50 of 0.45 nM, LRRK2 WT with an IC 50 of 1.1 nM, and LRRK2 WT ADP-Glo with an IC 50 of 0.46 nM. This compound is utilized in research related to Alzheimer's Disease [1].Formula:C18H17ClN8O2Color and Shape:SolidMolecular weight:412.83SRI-31255
CAS:SRI-31255 is an orally active LRRK2 inhibitor, with IC50 values of 520 nM for human wild-type (WT) and 427 nM for the G2019S mutant. It inhibits kinase activity by binding to the ATP-binding pocket of LRRK2, providing neuroprotective effects. SRI-31255 serves as a lead compound for developing LRRK2-targeted therapies for Parkinson’s disease research.Formula:C15H14N4Color and Shape:SolidMolecular weight:250.30LRRK2-IN-20
CAS:LRRK2-IN-20 (EX. 4.64) is a selective inhibitor of LRRK2 with a potency of pIC50 at 0.7921 nM. This compound is applicable in research studies focused on Parkinson's Disease (PD).Formula:C24H32ClN7OColor and Shape:SolidMolecular weight:470.01LRRK2-IN-3
CAS:LRRK2-IN-3: potent, selective oral LRRK2 blocker, BBB-penetrant, IC50 of 0.6 nM in hPBMCs, for Parkinson's research.Formula:C25H29ClF2N6O2Color and Shape:SolidMolecular weight:518.99LRRK2-IN-4
CAS:LRRK2-IN-4: Potent, selective LRRK2 inhibitor, oral, BBB-penetrating, IC50=2.6 nM, potential for Parkinson's.Formula:C25H29ClF2N6O2Color and Shape:SolidMolecular weight:518.99
